Similar articles

• Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors.

  Gutteridge E, Robertson JF. Gutteridge E, et al. Breast Cancer Res. 2009;11 Suppl 3(Suppl 3):S24. doi: 10.1186/bcr2443. Epub 2009 Dec 18. Breast Cancer Res. 2009. PMID: 20030876 Free PMC article. No abstract available.
• Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib.

  Burris HA 3rd. Burris HA 3rd. Oncologist. 2004;9 Suppl 3:10-5. doi: 10.1634/theoncologist.9-suppl_3-10. Oncologist. 2004. PMID: 15163842 Review.
• Inhibition of c-ABL sensitizes breast cancer cells to the dual ErbB receptor tyrosine kinase inhibitor lapatinib (GW572016).

  Lo YH, Ho PC, Zhao H, Wang SC. Lo YH, et al. Anticancer Res. 2011 Mar;31(3):789-95. Anticancer Res. 2011. PMID: 21498698
• Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.

  Jo Chien A, Rugo HS. Jo Chien A, et al. Cancer Treat Res. 2009;151:197-215. doi: 10.1007/978-0-387-75115-3_13. Cancer Treat Res. 2009. PMID: 19593514 Review. No abstract available.
• ErbB/HER receptor family in breast cancer--the more we search the more we learn.

  Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG. Karamouzis MV, et al. Ann Oncol. 2008 May;19(5):1020-1. doi: 10.1093/annonc/mdn061. Epub 2008 Mar 19. Ann Oncol. 2008. PMID: 18356136 No abstract available.